Arvinas price to sales ratio ARVN

Market value divided by revenue over the last twelve months, since 2019.

Today, Oct 23, 2026: 1.5×
8-year median: 28.7×
Against its 8-year history: 0th; percentile: 0 is its lowest day, 100 its highest
8-year range: 1.4× to 200×
Peer median: 1.5×

Arvinas' price to sales ratio is 1.5× as of Oct 23, 2026.

That is below its 8-year median of 28.7×, lower than on 100% of days in the last 8 years.

Over that time it ranged from 1.4× in Oct 2026 to 200× in Oct 2021.

The median for 10 large drugmakers of a similar size is 1.5×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	1.5×	1.4×	6.6×
2025	n/m a value too high to mean anything
2024	13.4×	12.0×	19.3×
2023	13.5×	4.7×	16.8×
2022	16.2×	15.5×	178×
2021	192×	125×	200×
2020	141×	17.5×	141×
2019	34.0×	20.7×	62.7×

Against its peers

Companies in Drug Manufacturers - General nearest Arvinas' size, closest first, today.

Company	Price to sales ratio
ARVNArvinas	1.5×
PBYIPuma Biotechnology	2.5×
IRWDIronwood Pharmaceuticals	1.5×
ZVRAZevra Therapeutics	4.3×
CRMDCorMedix	1.3×
COLLCollegium Pharmaceutical	0.9×
ABUSArbutus Biopharma	4.6×
NATRNatures Sunshine Products	0.4×
AMPHAmphastar Pharmaceuticals	1.5×
OMEROmeros	n/m
PCRXPacira BioSciences	1.9×
Peer median	1.5×

Where Arvinas ranks

#32of 157Large drugmakers with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Arvinas

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.